639 results on '"Stadler, Walter M"'
Search Results
2. Bladder-Preserving Trimodality Therapy With Capecitabine
3. A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer
4. Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors
5. Comparison of out-of-pocket costs and adherence between the two arms of the prospective, randomized abiraterone food effect trial
6. A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience
7. KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation
8. Optimizing the doses of cancer drugs after usual dose finding.
9. NF2-mutated Renal Carcinomas Have Common Morphologic Features Which Overlap With Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma: A Comprehensive Study of 14 Cases
10. KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer
11. Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report
12. Patient-provider communications about pharmacogenomic results increase patient recall of medication changes
13. Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma
14. Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer
15. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma
16. Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer
17. Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)
18. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
19. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
20. A Phase II Study of AT-101 to Overcome Bcl-2–Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer
21. Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study
22. EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells
23. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy
24. Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)
25. Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer
26. Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib
27. Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)
28. Evaluation of the Prostate Bed for Local Recurrence After Radical Prostatectomy Using Endorectal Magnetic Resonance Imaging
29. Estimation of Progression-Free Survival for All Treated Patients in the Randomized Discontinuation Trial Design
30. Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
31. Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate Cancer
32. The Combination of Insulin-Like Growth Factor Receptor 1 (IGF1R) Antibody Cixutumumab and Mitotane as a First-Line Therapy for Patients with Recurrent/Metastatic Adrenocortical Carcinoma: a Multi-institutional NCI-Sponsored Trial
33. Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study
34. Eosinophilic renal cell carcinoma with isolated MTOR mutation metastatic to the liver: a novel case
35. Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer
36. Dose-Escalated Radiotherapy for High-Risk Prostate Cancer: Outcomes in Modern Era With Short-Term Androgen Deprivation Therapy
37. Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial
38. Angiokines associated with outcomes after sunitinib or everolimus treatment in patients with non-clear cell renal cell carcinoma
39. Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial
40. Variability in Surgical Quality in A Phase III Clinical Trial of Radical Cystectomy in Patients With Organ-Confined, Node-Negative Urothelial Carcinoma of the Bladder
41. Progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?
42. Adjuvant chemotherapy in lymph node positive bladder cancer
43. Phase II Trial of Carboplatin and Paclitaxel in Papillary Renal Cell Carcinoma
44. Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.
45. Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium
46. A phase I study of continuous infusion cilengitide in patients with solid tumors
47. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium
48. Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma
49. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia
50. Vascular Endothelial Growth Factor Pathway—Targeted Therapy as Initial Systemic Treatment of Patients with Renal Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.